Clinical Nuclear Medicine for Oncology and Neurology
This community focuses on the use of radiotracers and advanced imaging technologies to diagnose, stage, and monitor cancer and brain disorders.
The work centers on Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT), frequently combined with Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). Recurring applications include the evaluation of lymph node metastasis, particularly sentinel lymph node biopsy in breast cancer, and the assessment of central nervous system pathologies such as glioblastoma and large B-cell lymphoma. The literature also covers the use of specific radiotracers like 18F-FDG and Indocyanine Green, alongside emerging applications of deep learning for image analysis and molecular imaging for primary hyperparathyroidism.
The community is most heavily weighted toward Technetium research, accounting for 14.3% of all Technetium studies, and Thallium, representing 3.2% of that element’s research. In terms of raw volume, the community contains 2,639 papers related to Technetium and 1,710 related to Fluorine.
The community comprises 37,487 papers, published primarily in the European Journal of Nuclear Medicine and Molecular Imaging, Clinical Nuclear Medicine, and Nuclear Medicine Communications.
Recent work includes the 2025 St Gallen Consensus Statement on individualizing therapy for early breast cancer and studies on artificial intelligence for glioma diagnosis using radiomics and deep learning across PET and MRI.